Literature DB >> 15240596

Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing.

Andrew R Hoffman1, Christian J Strasburger, Anthony Zagar, Werner F Blum, Anne Kehely, Mark L Hartman.   

Abstract

To determine whether an individualized dose titration regimen (ID) for adult GH replacement therapy would have similar efficacy and better tolerability than a fixed body weight-based dosing regimen (FD), 387 adults with GH deficiency were randomized to FD (n = 200) or ID (n = 187) for 32 wk. In FD, subjects received sequentially 4, 8, and 12 microg/kg.d GH. ID was started at 0.2 mg/d and increased by 0.2-mg/d increments, based on clinical and serum IGF-I responses, to a maximum of 0.8 mg/d. Increases (mean +/- sd) in serum IGF-I were similar in both groups (FD, 110.2 +/- 87.8 vs. ID, 99.6 +/- 77.7 microg/liter, P = 0.20) despite higher final GH doses in FD (0.70 +/- 0.32 vs. 0.54 +/- 0.22 mg/d, P < 0.001). Favorable changes in several efficacy measures were observed with no significant differences between the FD and ID groups: lean body mass increased; health-related quality of life improved; and abdominal fat mass, hip circumference, sum of skinfolds, and total and low-density lipoprotein cholesterol decreased. The decrease in fat mass was greater with FD than ID for men (-2.7 +/- 2.7 kg vs. -1.8 +/- 2.5 kg, P = 0.04) but not for women (-2.1 +/- 2.4 vs. -2.0 +/- 3.8 kg). The change in waist circumference was greater with FD than ID for women but not for men. There was a significant reduction of systolic blood pressure in ID but not in FD. The adverse event profile was similar between FD and ID except that ID had a lower occurrence of peripheral edema (9.1% vs. 16.5%, P = 0.03) and rash (1.1% vs. 5.5%, P = 0.02) than FD. In summary, the use of ID resulted in improved tolerability and similar efficacy compared with FD. We conclude that GH replacement therapy should be initiated at a low dose and titrated to a dose producing maximal benefits without adverse side effects and an IGF-I level within the age- and sex-adjusted normal range.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240596     DOI: 10.1210/jc.2003-032082

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  Anterior pituitary hormone replacement therapy--a clinical review.

Authors:  Christoph J Auernhammer; George Vlotides
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 2.  Changes in pituitary function with ageing and implications for patient care.

Authors:  Johannes D Veldhuis
Journal:  Nat Rev Endocrinol       Date:  2013-02-26       Impact factor: 43.330

3.  Optimized clinical performance of growth hormone with an expanded genetic code.

Authors:  Ho Cho; Tom Daniel; Ying Ji Buechler; David C Litzinger; Zhenwei Maio; Anna-Maria Hays Putnam; Vadim S Kraynov; Bee-Cheng Sim; Stuart Bussell; Tsotne Javahishvili; Sami Kaphle; Guillermo Viramontes; Mike Ong; Stephanie Chu; G C Becky; Ricky Lieu; Nick Knudsen; Paola Castiglioni; Thea C Norman; Douglas W Axelrod; Andrew R Hoffman; Peter G Schultz; Richard D DiMarchi; Bruce E Kimmel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

Review 4.  How useful are serum IGF-I measurements for managing GH replacement therapy in adults and children?

Authors:  Anna Pawlikowska-Haddal; Pinchas Cohen; David M Cook
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 5.  Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.

Authors:  A Giustina; A Barkan; P Chanson; A Grossman; A Hoffman; E Ghigo; F Casanueva; A Colao; S Lamberts; M Sheppard; S Melmed
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

6.  12-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency.

Authors:  Beverly M K Biller; Hyi-Jeong Ji; Hyunji Ahn; Conrad Savoy; E Christine Siepl; Vera Popovic; Mihail Coculescu; Josefine Roemmler; Catalin Gavrila; David M Cook; Christian J Strasburger
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

7.  Provocative stimulation of growth hormone: a monozygotic twin study discordant for spinal cord injury.

Authors:  William A Bauman; Run Lin Zhang; Ann M Spungen
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

8.  A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults.

Authors:  Kevin C J Yuen; Gerard S Conway; Vera Popovic; George R Merriam; Timothy Bailey; Amir H Hamrahian; Beverly M K Biller; Mark Kipnes; Jerome A Moore; Eric Humphriss; George M Bright; Jeffrey L Cleland
Journal:  J Clin Endocrinol Metab       Date:  2013-04-12       Impact factor: 5.958

9.  Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement.

Authors:  Mary L Reed; George R Merriam; Atil Y Kargi
Journal:  Front Endocrinol (Lausanne)       Date:  2013-06-04       Impact factor: 5.555

Review 10.  Individual sensitivity to growth hormone replacement in adults.

Authors:  Cesar Luiz Boguszewski
Journal:  Rev Endocr Metab Disord       Date:  2020-10-07       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.